Free Trial

Merck & Co (MRK: A1 pos / A+): Earnings 30th July

HEALTHCARE
  • Analysts' earnings expectations have DROPPED -5% on average in the past month.
  • Given that this is covered by 20 analysts there is clearly something happening.
  • FY24 EPS expected $8.19 from $8.60
  • MRK is a large issuer with $38bn in bonds spread over 14.4 WtgAve Years.
  • $3bn total expiring in next 6 months.
  • Last issued EUR 3.4bn in May to pay for Elanco Animal Health.
  • Merck has a very heavy R&D programme ($30b has tripled since 2020) on top of M&A to attempt to replace Keytruda as its main revenue source (45% sales).
  • Keytruda loses patent in 2028.
  • Market will want information on the integration of Prometheus, Acceleron , Elanco and Eyebiotech. Management will be busy.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.